LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

Search

Verve Therapeutics Inc

Closed

6.27 1.46

Overview

Share price change

24h

Current

Min

5.93

Max

6.37

Key metrics

By Trading Economics

Income

19M

-31M

Sales

20M

33M

EPS

-0.35

Profit margin

-94.108

Employees

274

EBITDA

19M

-35M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+289.61% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

156M

544M

Previous open

4.81

Previous close

6.27

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Verve Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 cze 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

KKR to Acquire Australian Power Provider Zenith Energy

16 cze 2025, 21:55 UTC

Major Market Movers

Geospace Technologies Shares Up on Petrobras Pact

16 cze 2025, 17:04 UTC

Major Market Movers

Roku Shares Climb on Advertising Deal with Amazon

16 cze 2025, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 cze 2025, 23:51 UTC

Market Talk

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16 cze 2025, 23:41 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16 cze 2025, 23:10 UTC

Market Talk
Acquisitions, Mergers, Takeovers

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16 cze 2025, 23:02 UTC

Market Talk

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16 cze 2025, 22:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16 cze 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16 cze 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16 cze 2025, 21:56 UTC

Earnings

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16 cze 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16 cze 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

16 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 cze 2025, 20:49 UTC

Market Talk

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16 cze 2025, 20:13 UTC

Market Talk

Natural Gas Gains on Warmer Outlook -- Market Talk

16 cze 2025, 19:58 UTC

Acquisitions, Mergers, Takeovers

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16 cze 2025, 19:13 UTC

Market Talk

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16 cze 2025, 19:09 UTC

Market Talk

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16 cze 2025, 18:43 UTC

Market Talk

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16 cze 2025, 18:36 UTC

Market Talk

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16 cze 2025, 18:29 UTC

Market Talk

Global Equities Roundup: Market Talk

16 cze 2025, 18:29 UTC

Market Talk

Shopify Appears More Resilient Than Feared -- Market Talk

16 cze 2025, 18:22 UTC

Market Talk

Citi Forecasts Downturn in Gold Futures -- Market Talk

16 cze 2025, 16:42 UTC

Market Talk

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16 cze 2025, 16:37 UTC

Market Talk

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16 cze 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Verve Therapeutics Inc Forecast

Price Target

By TipRanks

289.61% upside

12 Months Forecast

Average 24 USD  289.61%

High 39 USD

Low 15 USD

Based on 10 Wall Street analysts offering 12 month price targets forVerve Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

4.1501 / 5.16Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.